# Breast Cancer Survival Analysis Model
## 3 Results
### Case Description  
#### 3.1.1 Kaplan-Meier Survival Analysis  
According to the Kaplan-Meier survival analysis for BC, the age of diagnosis was 84.13 \(\pm\) 0.916 and 85.491 \(\pm\) 0.420 months for patients >45 years and <45 years, respectively. The survival analysis of BC at the age of diagnosis indicated no significant difference in the number of months of survival at the age of diagnosis, whereas the log-rank test = 0.148 (>0.05) indicated no statistically significant difference between the age of diagnosis and survival time. BC Morphology  
The Kaplan-Meier survival analysis for breast cancer morphology was 84.697 \(\pm\) 0.303 months for carcinoma in situ cancer and the mean survival months for invasive carcinoma was 84.672 \(\pm\) 0.458. Although the survival analysis of breast cancer morphology showed that there was no significant difference in the number of months, the log-rank test = 0.004 (<0.05) indicated that there was a statistically significant difference in the survival time. The Kaplan-Meier survival analysis for BC graded differentiation had a mean survival of 86.194 \(\pm\) 0.793, 83.598 \(\pm\) 585, and 82.203 \(\pm\) 0.731 months for well-differentiated, moderately differentiated, and poorly differentiated, respectively. As shown in the graph, there was a significant difference in the number of months of survival for BC by the grade of differentiation, and the log-rank test = 0.032 (<0.05) indicated that there was a statistically significant difference in the survival time by the grade of differentiation. Survival analysis of surgical treatment for BC was 73.83 \(\pm\) 3.37 and 85.30 \(\pm\) 0.38 months without and with surgery, respectively. Survival analysis of the surgical treatment of BC indicated a significant difference in the number of months of survival with or without surgical treatment of BC, whereas the log-rank test = 0.017 (<0.05) indicated a statistically significant difference in the survival time with or without special treatment of BC. Survival analysis of radiation therapy for BC was 85.45 \(\pm\) 0.55 and 84.86 \(\pm\) 0.57 months without and with radiation therapy, respectively. Survival analysis of BC radiation therapy indicated no significant difference in the number of months of survival with or without BC radiation therapy, whereas the log-rank test for radiation therapy = 0.365 (>0.05) indicated no statistically significant difference in the survival time with or without BC radiation therapy. Chemotherapy  
Survival analysis of chemotherapy for BC was 85.03 \(\pm\) 0.35 and 83.88 \(\pm\) 0.60 months without and with chemotherapy, respectively. A significant difference was detected in the number of months survived with or without chemotherapy for BC, while the log-rank test for chemotherapy = 0.000 (<0.05) indicated a statistically significant difference in survival time with or without chemotherapy for BC. Survival analysis of hormonal treatment for BC was 80.57 \(\pm\)1.24 months without hormonal treatment and 86.62 \(\pm\) 0.32 months with hormonal treatment. Survival analysis of hormone therapy for BC indicated no significant difference in the number of months of survival with or without hormone therapy for BC, whereas the log-rank test = 0.000 (<0.05)for hormone therapy indicated a statistically significant difference in survival time with or without hormone therapy for BC. Table 2 and Figure 3 demonstrate the Kaplan-Meier survival analysis of the BC estrogen hormone receptor test. The average survival months in the (\(-\)) negative group were 82.512 \(\pm\) 0.951 months, the average survival months in the (+) low positive group were 85.463 \(\pm\) 0.759 months, and the average survival months in the (+) medium positive group were 84.532 \(\pm\) 0.533 months. The average survival months for (+) high positives were 86.703 \(\pm\) 0.432 months, whereas 80.00 \(\pm\) 0.806 months for (+) were positive unknowns.